Characterization and Transmission Dynamics of Carbapenemase Genes in Carbapenem-Resistant Enterobacter cloacae: Insights from Guangdong Province (2022–2024)

Study Background and Research Question

Carbapenem-resistant Enterobacteriaceae (CRE) represent a mounting global public health threat, with Enterobacter cloacae among the leading contributors to multidrug-resistant (MDR) infections. In China, the prevalence of carbapenem-resistant E. cloacae (CREC) is rising, complicating treatment options and increasing nosocomial risks. A major driver of resistance in these organisms is the acquisition and dissemination of carbapenemase-encoding genes (CEGs), particularly within hospital environments. However, detailed epidemiological and molecular insights into CEG carriage, localization, and transmission dynamics in CREC, especially in the context of the COVID-19 pandemic, have remained limited. The reference study (Chen et al., 2025) addresses this gap by analyzing CREC strains from eight teaching hospitals in Guangdong, China, collected between December 2022 and June 2024.

Key Innovation from the Reference Study

The principal innovation of this work lies in the integrated molecular and epidemiological mapping of CEGs within a regional, multi-institutional cohort of CREC. By combining high-resolution genetic characterization (including plasmid/chromosome localization, mobile genetic element profiling, and genotyping) with clinical metadata, the authors illuminate both the mechanisms of resistance and the real-world transmission dynamics in a pandemic-altered healthcare environment. Notably, the study quantifies the prevalence of key carbapenemase genes—such as bla_NDM−1, bla_IMP, and bla_KPC−2—and tracks their vectors of spread, providing actionable insights for infection control and antibiotic resistance research.

Methods and Experimental Design Insights

The study analyzed 54 non-redundant CREC isolates from eight tertiary teaching hospitals. Each isolate underwent the following workflow:

• PCR detection for CEGs, targeting bla_NDM−1, bla_IMP, and bla_KPC−2.
• Variable temperature SDS plasmid elimination to distinguish chromosomal from plasmid-borne genes.
• Plasmid conjugation experiments to assess horizontal transferability of CEGs.
• ERIC-PCR and NTSYS software-based genotyping to cluster isolates and infer epidemiological links.
• Broth microdilution for antimicrobial susceptibility profiling, focusing on both carbapenems and representative aminoglycosides (including gentamicin, mechanistically similar to amikacin).
• Mobile genetic element (MGE) mapping to identify vectors facilitating gene movement.

This multi-pronged approach enabled the authors to dissect not only the genetic basis of resistance, but also the efficiency and context of CEG transfer among clinical isolates.

Core Findings and Why They Matter

• High CEG Prevalence and Distribution: 85.19% of CREC isolates carried CEGs (Chen et al., 2025), with bla_NDM−1 the most frequently detected gene. This gene was found both on plasmids and chromosomes, but most commonly on plasmids, highlighting the dominant role of mobile elements in resistance propagation.
• Efficient Horizontal Gene Transfer: Plasmid conjugation and PCR analyses revealed a 95.65% success rate for transfer of CEGs, especially bla_NDM−1 and bla_IMP, which were highly mobile. Such efficiency underscores the risk of rapid inter-strain dissemination in hospital settings.
• Multidrug Resistance Profiles: CEG-positive isolates exhibited significantly higher resistance rates to imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin than CEG-negative strains. The use of gentamicin as a comparator is notable given the mechanistic relatedness to amikacin, a bacterial protein synthesis inhibitor often used for resistance research.
• Genetic Diversity and Epidemiology: ERIC-PCR genotyping identified 17 distinct clusters, with two dominant types (E and G) prevalent across multiple hospitals. This pattern suggests both clonal expansion and inter-institutional transmission, likely exacerbated by healthcare disruptions during COVID-19.
• Mobile Genetic Elements: Six types of MGEs were documented, with ISEcp1 present in 87.04% of isolates and many strains carrying multiple MGEs, amplifying the risk of gene mobilization.
• Clinical Correlates: Higher CEG detection rates were observed among men, elderly patients, in respiratory medicine departments, and notably in sputum samples, indicating priority targets for surveillance.

Collectively, these findings illuminate the complex interplay between genetic, clinical, and epidemiological factors underpinning the spread of carbapenem resistance in E. cloacae in southern China.

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on resistance mechanisms and experimental approaches:

• "Amikacin (BAY416651): Mechanistic Mastery and Strategic Guidance" offers a mechanistic and workflow-focused discussion of amikacin use for dissecting resistance in multidrug-resistant Enterobacteriaceae, including Klebsiella pneumoniae and E. cloacae. The workflow recommendations align with the reference study’s emphasis on the importance of understanding both gene localization and transfer dynamics.
• "Amikacin (BAY416651): Applied Workflows and Resistance Research" expands on practical troubleshooting and reproducibility strategies when investigating resistance pathways using bacterial protein synthesis inhibitors. This is directly relevant for researchers using amikacin in susceptibility and resistance mechanism studies, as highlighted by the reference paper’s use of gentamicin as a phenotypic marker.
• "Applied Research with Amikacin: Advancing Antibiotic Resistance" underscores amikacin’s utility in distinguishing resistance phenotypes, particularly due to its resilience against most aminoglycoside-modifying enzymes—a property also important for interpreting susceptibility results in the face of widespread resistance genes.

While the reference study focuses on epidemiology and gene transfer, the internal articles provide practical laboratory guidance and highlight amikacin’s unique role in resistance research workflows.

Limitations and Transferability

Despite its strengths, the study is subject to several limitations:

• Geographic and Institutional Scope: The findings are based on isolates from eight hospitals within Guangdong Province; broader national or international patterns may differ.
• Temporal Coverage: The 18-month collection window captures COVID-19 pandemic effects but may not reflect longer-term trends.
• Focus on Selective Genes: The molecular characterization is centered on three CEGs (bla_NDM−1, bla_IMP, bla_KPC−2); other resistance determinants or mechanisms (e.g., efflux pumps, porin loss) are not addressed.
• Clinical Data Granularity: While general demographics and departments are reported, more granular patient-level data (such as comorbidity burden or antibiotic exposure history) are absent.

Nonetheless, the study’s approach—integrating molecular epidemiology with clinical context—provides a valuable blueprint for similar surveillance and resistance mechanism investigations elsewhere.

Protocol Parameters

• Plasmid elimination: Apply variable temperature SDS treatment to distinguish plasmid from chromosomal gene localization, as employed in the reference study.
• Conjugation efficiency assessment: Use broth mating protocols and PCR screening to confirm horizontal transfer of CEGs between donor and recipient strains.
• Genotyping for epidemiology: Employ ERIC-PCR and cluster analysis software (e.g., NTSYS) to identify outbreak clusters and infer transmission routes.
• Antibiotic susceptibility testing: Perform broth microdilution for key antibiotics (carbapenems, cephalosporins, aminoglycosides) to correlate genotype with phenotype.
• Mobile genetic element mapping: Screen for MGEs (e.g., ISEcp1) using PCR and sequencing to elucidate gene dissemination vectors.
• For aminoglycoside resistance research: Consider integrating amikacin as a comparator, especially given its resistance to most aminoglycoside-modifying enzymes, except for AAC(6')-I type enzymes (product information).

Research Support Resources

To replicate or extend these workflows in antibiotic resistance research, researchers may utilize Amikacin (BAY416651) Aminoglycoside Antibiotic (SKU B3431), a semi-synthetic aminoglycoside with proven resilience against most modifying enzymes and established use in resistance phenotyping with Klebsiella pneumoniae and Enterobacter cloacae. APExBIO provides research-grade amikacin suitable for these applications, as detailed in the internal workflow guide. For optimal experimental design, researchers are encouraged to review both molecular epidemiology and laboratory troubleshooting resources to maximize data reproducibility and translational impact.